Detalhe da pesquisa
1.
Non-KPC Attributes of Newer ß-lactamase/ß-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa.
Clin Infect Dis;
2024 Feb 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38306487
2.
Effects of clinically achievable pulmonary antibiotic concentrations on the recovery of bacteria: in vitro comparison of the BioFire FILMARRAY Pneumonia Panel versus conventional culture methods in bronchoalveolar lavage fluid.
J Clin Microbiol;
62(1): e0113323, 2024 01 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38112451
3.
Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales.
J Clin Microbiol;
: e0152023, 2024 May 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38712928
4.
Assessing the in vivo impact of novel ß-lactamase inhibitors on the efficacy of their partner ß-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
J Antimicrob Chemother;
79(3): 546-551, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38217443
5.
In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity.
J Antimicrob Chemother;
79(2): 412-416, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38153232
6.
Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
J Antimicrob Chemother;
79(5): 1118-1125, 2024 May 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38517465
7.
Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage.
J Antimicrob Chemother;
79(5): 1176-1181, 2024 May 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38562061
8.
In Vivo Pharmacodynamic Profile of EVER206, a Novel Polymyxin Antimicrobial, against Gram-Negative Bacteria in the Murine Thigh Infection Model.
Antimicrob Agents Chemother;
67(5): e0173822, 2023 05 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37022170
9.
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Antimicrob Agents Chemother;
67(11): e0092023, 2023 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37888987
10.
In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model.
J Antimicrob Chemother;
78(3): 692-702, 2023 03 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36640133
11.
In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales.
J Antimicrob Chemother;
78(12): 2801-2809, 2023 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37839896
12.
Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES ß-lactamases.
J Antimicrob Chemother;
78(8): 1843-1847, 2023 08 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37357368
13.
Phenotypes, genotypes and breakpoints: an assessment of ß-lactam/ß-lactamase inhibitor combinations against OXA-48.
J Antimicrob Chemother;
78(3): 636-645, 2023 03 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36626311
14.
Activity of novel ß-lactam/ß-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother;
78(12): 2795-2800, 2023 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37840005
15.
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
J Antimicrob Chemother;
78(4): 983-990, 2023 04 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36775993
16.
Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians.
J Antimicrob Chemother;
78(9): 2242-2253, 2023 09 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37522258
17.
Imipenem/funobactam (formerly XNW4107) in vivo pharmacodynamics against serine carbapenemase-producing Gram-negative bacteria: a novel modelling approach for time-dependent killing.
J Antimicrob Chemother;
78(9): 2343-2353, 2023 09 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37667103
18.
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.
J Antimicrob Chemother;
78(3): 703-709, 2023 03 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36617636
19.
Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
Crit Care;
27(1): 60, 2023 02 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36788582
20.
In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth.
Antimicrob Agents Chemother;
66(3): e0216721, 2022 03 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35007135